AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its proprietary boron chemistry platform. The company advances treatments for serious infectious diseases with high unmet needs, including non-tuberculous mycobacterial lung disease, acute melioidosis, chronic Chagas disease, and M. abscessus lung disease. Its lead candidate, epetraborole, is an oral therapy in phase 3 clinical trials for non-tuberculous mycobacterial lung disease and under investigation for additional indications such as polycythemia vera and melioidosis. AN2 Therapeutics also develops AN2-502998, a boron-based compound in early clinical stages for chronic Chagas disease, alongside research programs targeting tuberculosis, oncology, and other infectious diseases. Through strategic collaborations, including with GSK for tuberculosis therapies, the company leverages its platform to create potentially transformative medicines. Headquartered in Menlo Park, California, and incorporated in 2017, AN2 Therapeutics emphasizes global health initiatives to deliver impactful drugs that improve patient outcomes in rare and chronic conditions.